Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors

doi:10.3877/cma.j.issn.2095-5820.2017.04.005

Abstract

Abstract:

The VeriStrat test is a blood-based proteomic test with predictive and prognostic significance in treatment of non-small cell lung cancer (NSCLC). Mass spectra from these patients′ serum samples were classified into two outcome groups, VeriStrat-Good group and VeriStrat-Poor group which are used to evaluate different treatment outcomes. It also cam used for precision medicime of NSCLC. Our paper illustrates the current progress in the clinical application of VeriStrat test, and aims to investigate the clinical value of Veristrat test in the treatment of NSCLC and other tumors. In summary, VeriStrat test is helpful to promote the application of individualized treatments.

Key words: Non-small cell lung cancer, Individualized treatment, Tumors, VeriStrat

Feng Chen, Rong Zhang, Xinchao Liu, Song Cui, Jun Yang, Qingwei Ma, Chen Chen, Xiaoqing Zhang, Wei Cui. Application of VeriStrat test in individualized treatment of non-small cell lung cancer and other tumors[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2017, 05(04): 217-220.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2017.04.005

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2017/V05/I04/217

References 15

1	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016,66(1):7-30.
2	Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture[J]. Eur J Cancer, 2001,37 Suppl 8:S4-66.
3	宋晓燕，李积德，赵君慧. 非小细胞肺癌个体化靶向治疗进展[J]. 医药前沿, 2012(32): 27-28.
4	廉政君，黄建国. 晚期非小细胞肺癌预后相关因素分析[J]. 现代肿瘤医学, 2014,22(1): 95-97.
5	Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study[J]. J Nati Cancer Inst, 2007,99 (11):838-846.
6	Carbone DP, Salmon JS, Billheimer D, et al. VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab[J]. Lung Cancer, 2010,69(3):337-340.
7	Kuiper JL, Lind JS, Groen HJ, et al. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib[J]. Br J Cancer, 2012,107(11):1820-1825.
8	Lazzari C, Spreafico A, Bachi A, et al. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Thorac Oncol, 2012,7(1):40-48.
9	Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non–small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial[J]. J Thorac Oncol, 2012,7(11):1653-1660.
10	Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial[J]. Lancet Oncol, 2014,15(7):713-721.
11	Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4. 2016[J]. J Nati Compr Canc Netw, 2016,14(3):255-264.
12	Grossi F, Rijavec E, Genova C, et al. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy[J]. Br J Cancer, 2017,116(1):36-43.
13	Chung CH, Seeley EH, Roder H, et al. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients[J]. Cancer Epidemiol Biomarkers Prev, 2010,19(2):358-365.
14	Mazouni C, Baggerly K, Hawke D, et al. Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure[J]. Proteomics, 2010,10(19):3525-3532.
15	Gautschi O, Dingemans AM, Crowe S, et al. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528[J]. Lung Cancer, 2013,79(1):59-64.

[1]	Mai Zhang, Dajiang Song, Yonglin Zhang, Yumei Fu, Xiaodie Xu, Zhihua Tan, Shu Liu. Autologous breast reconstruction for defect repair of chest wall after breast phyllodes tumor surgery [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(03): 163-166.
[2]	Taiyuan Liu, Jun Li, Jiyue Gao, Haidong Zhao. Prognostic factor analysis and prognostic nomogram of malignant breast phyllodes tumors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(06): 346-352.
[3]	Ming Zhang, Ji Wang, Wenxing Zhao. Clinical application of limited pancreatic resection with pancreatic function preservation in benign and borderline tumors [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 562-565.
[4]	Jie Zhang, Yuan Lyu, Liang Sun, Hui Su, Hui Xie, Qiang Yuan, Xin Wang, Junfeng Du, Peng Jin, Gang Chen. Clinical analysis of combined laparoscope-gastroscopy for the treatment of difficult gastric stromal tumors [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 284-286.
[5]	. Radical resection of a rare giant gastrointestinal stromal tumor [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(02): 235-236.
[6]	Chen Lin, Meng Wang, Wenxian Guan, Feng Wang. Advances in immunotherapy and new strategies for gastrointestinal stromal tumor [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(01): 98-100.
[7]	Zhengdong Jiang, Xuqi Li, Shufeng Wang, Guangbing Wei. Laparoscopic surgery strategy for recurrent inguinal hernia and the observation of therapeutic effects [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(05): 539-543.
[8]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[9]	Yiran Li, Yuxiu Wang, Yan Zhu, Meng Wang, Ying Liu, Wenjin Yan, Xingxiang Xu, Lingfeng Min. Analysis of differential genes that affect the efficacy of Nivolumab and Pembrolizumab in the treatment of non-small cell lung cancer based on GEO database [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(01): 20-25.
[10]	Zhaohai Wang, Bing Liu, Zizheng Wang, Yang Wang, Guodong Zhao. Practice of robotic target-territory resection of liver tumor guided by watershed theory [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2023, 16(01): 33-37.
[11]	Jiayuan Wang, Xiaodong Wang. Progress in research of sarcopenia in digestive system malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 823-827.
[12]	Yihan Wu, Zhang Lei, Hongda Lu. Progress in understanding of role of MUC16/CA125 in diagnosis and treatment of benign and malignant tumors [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(05): 591-595.
[13]	Yafei Wang, Zhenbiao Wu. Application of autoantibodies in management of dermatomyositis patients [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 796-800.
[14]	Junxian Mo, Dong Huang, Lei Xian. Retrospective cohort study of video-assisted thoracoscopic thymectomy versus thoracoscopic thymectomy surgery for thymic tumors with R0 resection over 5 cm [J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2023, 10(01): 7-14.
[15]	Xiaoxuan Fan, Na Wang, Lihua Zhu, Liang Wang. Research progress of obesity-related tumors [J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2023, 09(03): 173-178.

Please choose a citation manager

Content to export